公开(公告)号：WO2008055072A3

公开(公告)日：2009-04-23

申请号：PCT/US2007082675

申请日：2007-10-26

Applicant: LPATH THERAPEUTICS INC ,  SABBADINI ROGER A ,  GARLAND WILLIAM A ,  STOLLER GLENN L

Inventor： SABBADINI ROGER A ,  GARLAND WILLIAM A ,  STOLLER GLENN L

IPC: A61K39/395 ,  C07K16/00 ,  C12P21/08

CPC classification number: A61K38/08 ,  A61K38/10 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/92

Abstract: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1 -phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1 -phosphate.

Abstract translation: 本发明涉及用于预防和治疗疾病和病症，特别是眼部疾病和病症的组合物和方法，其特征在于异常纤维发生或瘢痕形成，炎症和/或异常的新生血管形成或血管生成。 本发明的组合物和方法利用对生物活性脂质，鞘氨醇-1-磷酸及其变体特异性反应的免疫衍生部分，该部分能够降低靶向生物活性脂质的有效浓度。 在一个实施方案中，免疫衍生部分是对l-鞘氨醇-1-磷酸反应的人源化单克隆抗体。

公开(公告)号：WO2008070344A2

公开(公告)日：2008-06-12

申请号：PCT/US2007/082647

申请日：2007-10-26

Applicant: LPATH THERAPEUTICS, INC. ,  SABBADINI, Roger, A. ,  GARLAND, William, A. ,  HANSEN, Genevieve ,  JONES, Steven, Tarran ,  WILLIAMS, David, Gareth

Inventor： SABBADINI, Roger, A. ,  GARLAND, William, A. ,  HANSEN, Genevieve ,  JONES, Steven, Tarran ,  WILLIAMS, David, Gareth

IPC: A61K39/395

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

Abstract: The present invention relates to anti-SIP agents, for example, humanized monoclonal antibodies, and their uses for detection of SIP or for treatment of diseases and conditions associated with SIP.

Abstract translation: 本发明涉及抗SIP剂（例如人源化单克隆抗体）及其用于检测SIP或用于治疗与SIP相关的疾病和病症的用途。

公开(公告)号：WO2007053447A3

公开(公告)日：2007-07-05

申请号：PCT/US2006042027

申请日：2006-10-27

Applicant: LPATH THERAPEUTICS INC ,  SABBADINI ROGER A ,  GARLAND WILLIAM A ,  STOLLER GLENN L

Inventor： SABBADINI ROGER A ,  GARLAND WILLIAM A ,  STOLLER GLENN L

IPC: A61K39/395 ,  C07K16/00 ,  C12P21/08

CPC classification number: C07K16/18 ,  A61K31/685 ,  A61K2039/505 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to compositions and methods for the treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of the bioactive lipids. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphinxine- 1 -phosphate (SlP) or lysophosphophatidic acid (LPA).

Abstract translation: 本发明涉及用于治疗疾病和病症的组合物和方法，包括特征在于异常纤维发生或瘢痕形成，炎症和/或异常新生血管形成或血管发生的眼部疾病和病症。 本发明的组合物和方法利用对生物活性脂质特异性反应并且能够降低生物活性脂质的有效浓度的免疫衍生部分。 在一些实施方案中，免疫来源的部分是对膦酸1-磷酸（SlP）或溶血磷脂酰胆碱酸（LPA）具有反应性的单克隆抗体。

公开(公告)号：WO2006078336A2

公开(公告)日：2006-07-27

申请号：PCT/US2005039303

申请日：2005-10-28

Applicant: LPATH THERAPEUTICS INC ,  SABBADINI ROGER A ,  CAVALLI AMY L ,  GARLAND WILLIAM

Inventor： SABBADINI ROGER A ,  CAVALLI AMY L ,  GARLAND WILLIAM

IPC: A61K39/395 ,  A61K38/17

CPC classification number: C07K16/18 ,  A61K39/39533 ,  A61K2039/505 ,  C07K16/3076 ,  C07K2317/73 ,  A61K2300/00

Abstract: Monotherapies and combination therapies for treating hyperproliferative disorders are described, as are compositions for performing such methods.

Abstract translation: 描述了用于治疗过度增殖性疾病的单一疗法和联合疗法，以及用于实施这种方法的组合物。

公开(公告)号：WO2006078336A3

公开(公告)日：2006-07-27

申请号：PCT/US2005/039303

申请日：2005-10-28

Applicant: LPATH THERAPEUTICS, INC. ,  SABBADINI, Roger, A. ,  CAVALLI, Amy, L. ,  GARLAND, William

Inventor： SABBADINI, Roger, A. ,  CAVALLI, Amy, L. ,  GARLAND, William

IPC: G01N33/574

Abstract: Monotherapies and combination therapies for treating hyperproliferative disorders are described, as are compositions for performing such methods.

公开(公告)号：WO2008070344A3

公开(公告)日：2008-11-20

申请号：PCT/US2007082647

申请日：2007-10-26

Applicant: LPATH THERAPEUTICS INC ,  SABBADINI ROGER A ,  GARLAND WILLIAM A ,  HANSEN GENEVIEVE ,  JONES STEVEN TARRAN ,  WILLIAMS DAVID GARETH

Inventor： SABBADINI ROGER A ,  GARLAND WILLIAM A ,  HANSEN GENEVIEVE ,  JONES STEVEN TARRAN ,  WILLIAMS DAVID GARETH

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K16/18 ,  C07K16/38 ,  C12N5/10 ,  C12N5/12 ,  C12N15/00 ,  C12P21/08 ,  G01N33/53

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

Abstract: The present invention relates to anti-SIP agents, for example, humanized monoclonal antibodies, and their uses for detection of SIP or for treatment of diseases and conditions associated with SIP.

Abstract translation: 本发明涉及抗SIP剂，例如人源化单克隆抗体，以及它们用于检测SIP或用于治疗与SIP相关的疾病和病症的用途。

公开(公告)号：WO2008070344A9

公开(公告)日：2008-08-28

申请号：PCT/US2007082647

申请日：2007-10-26

Applicant: LPATH THERAPEUTICS INC ,  SABBADINI ROGER A ,  GARLAND WILLIAM A ,  HANSEN GENEVIEVE ,  JONES STEVEN TARRAN ,  WILLIAMS DAVID GARETH

Inventor： SABBADINI ROGER A ,  GARLAND WILLIAM A ,  HANSEN GENEVIEVE ,  JONES STEVEN TARRAN ,  WILLIAMS DAVID GARETH

IPC: A61K39/395

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

Abstract: The present invention relates to anti-SIP agents, for example, humanized monoclonal antibodies, and their uses for detection of SIP or for treatment of diseases and conditions associated with SIP.

Abstract translation: 本发明涉及抗SIP剂，例如人源化单克隆抗体，以及它们用于检测SIP或用于治疗与SIP相关的疾病和病症的用途。

公开(公告)号：WO2008055072A2

公开(公告)日：2008-05-08

申请号：PCT/US2007/082675

申请日：2007-10-26

Applicant: LPATH THERAPEUTICS, INC. ,  SABBADINI, Roger, A. ,  GARLAND, William, A. ,  STOLLER, Glenn, L.

Inventor： SABBADINI, Roger, A. ,  GARLAND, William, A. ,  STOLLER, Glenn, L.

IPC: A61K38/10

CPC classification number: A61K38/08 ,  A61K38/10 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/92

Abstract: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1 -phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1 -phosphate.

Abstract translation: 本发明涉及用于预防和治疗疾病和病症，特别是眼部疾病和病症的组合物和方法，其特征在于异常纤维发生或瘢痕形成，炎症和/或异常的新生血管形成或血管生成。 本发明的组合物和方法利用对生物活性脂质，鞘氨醇-1-磷酸及其变体特异性反应的免疫衍生部分，该部分能够降低靶向生物活性脂质的有效浓度。 在一个实施方案中，免疫衍生部分是对l-鞘氨醇-1-磷酸反应的人源化单克隆抗体。

公开(公告)号：WO2007053447A2

公开(公告)日：2007-05-10

申请号：PCT/US2006/042027

申请日：2006-10-27

Applicant: LPATH THERAPEUTICS, INC. ,  SABBADINI, Roger, A. ,  GARLAND, William, A. ,  STOLLER, Glenn, L.

Inventor： SABBADINI, Roger, A. ,  GARLAND, William, A. ,  STOLLER, Glenn, L.

IPC: A61K39/395 ,  A61K31/685

CPC classification number: C07K16/18 ,  A61K31/685 ,  A61K2039/505 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (SlP) or lysophosphatidic acid (LPA).

Abstract translation: 本发明涉及用于预防和治疗疾病和病症的组合物和方法，包括特征在于异常纤维发生或瘢痕形成，炎症和/或异常新生血管形成或血管发生的眼部疾病和病症。 本发明的组合物和方法利用对生物活性脂质特异性反应并且能够降低所述生物活性脂质的有效浓度的免疫衍生部分。 在一些实施方案中，免疫来源的部分是对鞘氨醇-1-磷酸（S1P）或溶血磷脂酸（LPA）具有反应性的单克隆抗体。